The Swiss Agency for Therapeutic Products, Swissmedic, has approved Sobi’s Alprolix (eftrenonacog alfa) for the treatment of haemophilia B.

Haemophilia is a genetic disorder that impairs the body's ability to clot the blood required to stop bleeding. It occurs in about one in 25,000 male births annually, and more rarely in females.

Alprolix is a recombinant factor IX Fc Fusion protein therapy and is indicated for on-demand, as well as prophylaxis treatment of previously treated haemophilia B patients.

Sobi haemophilia vice-president and medical therapeutic area head Krassimir Mitchev said: “The Swiss approval of Alprolix is an important milestone for the haemophilia community, offering the opportunity for people with haemophilia B to experience prolonged protection from bleeds.

"We will now focus on ensuring timely and sustainable access to Alprolix in Switzerland."

“We will now focus on ensuring timely and sustainable access to Alprolix in Switzerland.”

According to the World Federation of Haemophilia estimates, approximately 28,000 people are currently diagnosed with haemophilia B worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

People with haemophilia B experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages.

Alprolix has been developed for haemophilia B by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1.

It is currently approved for the treatment of haemophilia B in the EU, Iceland, Liechtenstein and Norway, as well as the US, Canada, Japan, Australia, New Zealand and other countries.